Planview Acquires AI/ML Leader Aptage
Planview® today announced the acquisition of Aptage, a technology leader and pioneer in the application of Artificial Intelligence (AI) and Machine Learning (ML) to portfolio management and work management.
Aptage’s expertise in data science is combined with unique domain knowledge in the economics of development spanning Agile and project methodologies. The company’s technology and IP is focused on the application of AI/ML to enterprise software, offering customers early insights and visibility into anticipated value and delivery risk across traditional project management and agile methodologies. For Planview customers, this ultimately means more accurate project outcome forecasting, regardless of work methodologies and processes used to get work done.
“In today’s disruptive environment, the companies with early insights are the ones that can pivot more quickly to create competitive advantage,” said Greg Gilmore, CEO of Planview. “Aptage’s innovative AI/ML technology creates insights into project value and delivery risk, improving and strengthening the strategy to delivery pipeline. We’re excited to welcome Aptage into the Planview family and bring this expertise to our customers.”
“Aptage and Planview share a common vision for the future of AI/ML within portfolio management and work management,” said John Heintz, co-founder and CEO of Aptage. “We’re thrilled to be taking this next step together, expanding the reach of our technology and driving better outcomes for organizations.”
Founded in 2016, Aptage’s proprietary IP was designed to accommodate the small data characteristics of Agile and traditional projects to continuously learn, predict, and provide actionable advice throughout the strategy to delivery pipeline. The technology has been proven with early adopters and is ready to scale to the mainstream market with Planview.
John Heintz, co-founder and CEO, and Dr. Murray Cantor, co-founder and CTO, will be joining Planview, bringing extensive experience and unique expertise to the company. Heintz is a recognized thought leader in the Agile and Lean community with 20 years of hands-on experience, and will be joining to lead product management for AI/ML. Dr. Cantor joins Planview as the company’s Chief Data Scientist, a new role created in recognition of the momentum in data science and the application of AI/ML in enterprise software.
Planview will be embedding the Aptage AI/ML IP across the Planview product portfolio. We anticipate the Aptage technology being available to customers later this year. To learn more, visit: Planview.com.
Additional Resources:
- Aptage website
- Register for Planview Horizons– Sept 15-16, 2020
- Follow the Planview Blog
- Connect with Planview on Twitter, Facebook and LinkedIn
About Planview
Planview has one focus: enabling the transformation journey as organizations rewire strategy to delivery in today’s fast-paced, highly disruptive markets. Our solutions uniquely help organizations navigate this journey and accelerate on-strategy delivery at enterprise scale. Planview’s full spectrum of Portfolio Management and Work Management solutions create organizational focus on the strategic outcomes that matter and empower teams to deliver their best work, no matter how they work. The comprehensive Planview platform and enterprise success model enable customers to deliver innovative, competitive products, services, and customer experiences. Headquartered in Austin, Texas, Planview has more than 700 employees supporting 3,500 customers and 1 million users worldwide. For more information, visit: https://www.planview.com/.
Planview and the Planview logo are registered trademarks of Planview, Inc. All other trademarks are property of their respective owners.
About Aptage
Aptage is a technology leader and pioneer in the application of Artificial Intelligence (AI) and Machine Learning (ML) to portfolio and work management, enabling companies to use their own data more intelligently through schedule, cost, and prioritization solutions. Companies using Agile, Waterfall, or hybrid frameworks have used Aptage to learn more from their project data and make informed business decisions based on AI advice. For more information, visit: https://get.aptage.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200709005606/en/
Contact information
Planview
Leslie Marcotte, 719-439-4921
lmarcotte@planview.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 202517.9.2025 08:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced new 24-week interim data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). These data will support the planned regulatory submissions for povorcitinib in HS in Europe and the United States in 2025 and early 2026, respectively. The presentation will take place today at 2:45 p.m. CEST during a late-breaking oral presentation (Session: Late Breaking News; Presentation ID D1T01.1C) at the European Association of Dermatology and Venereology (EADV) 2025 Congress. “HS remains a challenging and often debilitating condition and many patients are in need of new, well-tolerated and effective therapies that address prominent signs and symptoms of the disease, including inflammatory lesions and pain,” said Pablo J. Cagnoni, M.D., President and Head of Res
Galderma’s Groundbreaking Real-World Study Reveals the Biological Toll of Modern Living and Urban Environments on Sensitive Skin17.9.2025 08:00:00 EEST | Press release
Galderma today announced new data from a first-of-its-kind real-world clinical study conducted in China assessing the biological impact of different lifestyles and their associated environmental factors on individuals with sensitive skin.1 Results from the study, conducted by dermatology experts from Galderma’s Global Sensitive Skincare Faculty (GSSF), will be presented at the European Academy of Dermatology and Venereology (EADV) 2025 Congress on Friday, September 19. The findings provide compelling evidence that modern, urban lifestyles are associated with worsened skin health in people with sensitive skin.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250916245806/en/ Sensitive skin affects up to 70% of people globally – a figure that has risen by 68% over the past two decades – yet it remains widely overlooked and under-studied.2,3 As more people live fast-paced lives in densely populated urban cities, growing evidence
Overture Life Launches European Preorder Waitlist for DaVitri, the World’s First Microfluidics-Based Automated Vitrification Platform17.9.2025 08:00:00 EEST | Press release
Overture Life, the innovator modernizing IVF to optimize reproductive freedom, today announced the launch of its European preorder waitlist for DaVitri, the world’s first automated vitrification platform. The waitlist ensures in vitro fertilization (IVF) facilities will be among the first in Europe to harness DaVitri to reduce manual workloads for their embryologists while eliminating operator variability, thereby providing patients with faster, more consistent procedures. As infertility rates spike worldwide, interest in egg freezing continues to rise while the infrastructure to support it lags behind. Egg freezing requires vitrification, typically a time-intensive, manual process vulnerable to human error that can only be performed by extensively trained embryologists. This has resulted in variability in egg and embryo survival rates that directly impact IVF success, as well as significant access issues caused by the throughput bottleneck. DaVitri automates egg vitrification, deliver
Ant International Recognized as an Inaugural Foreign Institution Partner by China’s Cross-Border Interconnection Payment Gateway17.9.2025 07:24:00 EEST | Press release
Ant International is appointed as an inaugural foreign Institution Partner (FIP) of China’s Cross-border Interconnection Payment Gateway (CPG), under the guidance of the People’s Bank of China and the Payment & Clearing Association of China (PCAC). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250916704996/en/ Eric Jing, Chairman of Ant Group and Ant International, and Cyril Han, CEO of Ant Group, celebrating China's Top International consumer destinations with card and wallet partners. Ant International and Alipay are the largest player in the CPG scheme with the largest number of card network and wallet partners, the broadest use cases and largest business volume. The new CPG scheme is designed to raise connection efficiency and improve system stability for overseas payment partners. Its timely launch opens a safe and smoother highway for these partners to access the Chinese market. Alipay+, the cross-border payment and d
Ant International Joins Google's Agent Payments Protocol as a Launch Partner17.9.2025 07:00:00 EEST | Press release
Ant International, a leading global provider of digital payments, digitisation, and financial technology, today announced its role as a launch partner of Google to develop Agent Payments Protocol (AP2), an open rulebook that defines how AI agents can reliably transact with the authorisation of users. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250916339888/en/ With the rise of agentic commerce, AI agents will increasingly transact on behalf of users for services, products, and even other agents. Existing payment systems are built around direct human interaction and cannot currently address the new requirements of authorization, verification, and interoperability among agents. To address this gap, Google has collaborated with the industry to introduce AP2. AP2 defines the key components of agentic payments and provides a protocol to ensure user intent is verifiable, transactions are traceable, and accountability is clear f
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom